Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.66 |
| ▸ | CES1 | P23141 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568852 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL306625 | 0.84 | ALDH1A1 (0.59) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL12498251 | 0.83 | ERN1 (0.57) | ALDH1A1CES2CES1HTTMAPT | |
| SCHEMBL11783898 | 0.83 | TSHR (0.67) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL24497088 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL11362571 | 0.82 | OPRM1 (0.65) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL4604584 | 0.82 | ATM (0.63) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL3933924 | 0.82 | ALDH1A1 (0.56) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL12263647 | 0.82 | ALDH1A1 (0.60) | ALDH1A1CES2CES1TP53TSHR | |
| SCHEMBL29636506 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CES2CES1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120554814-A | Antibacterial moisture-permeable polyester material and preparation method thereof | 张家港和创新材料科技有限公司 | 2025-08-29 | — | — | CN | disclosed |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-06-12 | — | — | US | disclosed |
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-02-11 | — | — | US | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117561262-A | Macrocyclic TAK1 inhibitors | 阿奎利恩有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-116354889-A | Process for preparing benzimidazole derivatives | 怡诺安有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116143779-A | Compound of hematopoietic progenitor cell kinase 1 inhibitor, preparation method and application thereof | 中国药科大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| CN-108290860-B | Iminotetrahydropyrimidinone derivatives as PLASMEPSIN V inhibitors | UCB生物制药有限责任公司 | 2021-08-10 | — | — | CN | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5696110-A | ANTIULCER AGENTS | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-09 | — | — | US | disclosed |
| EP-0807104-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT 2C? RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-11-19 | — | — | EP | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| WO-1996023769-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT2C RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| CN-1097417-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | CN | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0609306-A1 | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF CHOLECYSTOKININ AND/OR GASTRIN RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993008176-A1 | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF CHOLECYSTOKININ AND/OR GASTRIN RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539170-A1 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors | MERCK SHARP & DOHME LTD. (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | WEE1, WEE2, NME1 | ALDH1A1 3933/4885CES2 2891/4885CES1 1348/4885 |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | ALDH1A1 3933/4885CES2 2891/4885CES1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.